Ultragenyx Pharmaceutical Inc. has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million in cash. The company was awarded this voucher by the FDA in August 2026 upon the approval of its drug, GENGLYCOS™, for glycogen storage disease type Ia (GSDIa).
Key Details
- Agreement Date: October 6, 2026.
- Sale Price: The buyer will pay $210 million in cash upon closing.
- NIH Payment: Per a 2018 patent license agreement, Ultragenyx will pay 20% of the gross proceeds ($42 million) to the National Institutes of Health (NIH) after the transaction closes.
- Closing Conditions: The sale is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.